JULIET Phase 2 trial

September 25, 2018

NICE Rejects Kymriah for England’s NHS to Treat Aggressive DLBCL

News

Kymriah (tisagenlecleucel), developed by Novartis, has not been recommended as a treatment for adults with aggressive diffuse large B-cell lymphoma (DLBCL) for England’s National Health Service (NHS). The National Institute for Health ... Read more

January 18, 2018January 18, 2018

FDA Promises Rapid Review of Kymriah for Diffuse Large B-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) will prioritize the regulatory review of Novartis’ application to use Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory diffuse large ... Read more

November 8, 2017

Novartis Files for Approval of Kymriah for Two Blood Cancers in the EU

News

Novartis continues the process of making Kymriah (tisagenlecleucel) commercially available outside the U.S., now by applying with the European Medicines Agency (EMA) to approve the treatment for two types of ... Read more

November 2, 2017

Novartis Asks FDA to Approve Kymriah for Difficult-to-treat DLBCL

News

Novartis has asked U.S. regulators to expand their approval of Kymriah (tisagenlecleucel) to include the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, or DLBCL. The Food ... Read more

April 20, 2017

Novartis’ CTL019 Receives Breakthrough Therapy Designation for the Treatment of Certain DLBCL Patients

News

Novartis‘ CAR T-cell therapy CTL019 has received breakthrough therapy status by the U.S. Food and Drug Administration for the treatment of adult patients with relapsed and refractory diffuse large B-cell ... Read more